SCHEMBL354573

SCHEMBL354573

CCCNCCCS(=O)(=O)O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 1/20 0.52
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.46
EPHX2 P34913 1/20 0.42
APP P05067 1/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
RELA Q04206 4/20 0.40
S1PR2 O95136 5/20 0.39
S1PR4 O95977 5/20 0.39
S1PR1 P21453 5/20 0.39
S1PR3 Q99500 5/20 0.39
S1PR5 Q9H228 1/20 0.39
PPARA Q07869 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
ADH1B P00325 1/20 0.37
ADH1A P07327 1/20 0.37
ADH7 P40394 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15305904 0.95 PAOX (0.52) PAOXALDH1A1TSHREPHX2APP
Tetramethylammonium Ion SCHEMBL10009677 0.94 PAOX (0.47) PAOXALDH1A1TSHREPHX2APP
SCHEMBL22800826 0.93 PAOX (0.50) PAOXALDH1A1TSHREPHX2APP
SCHEMBL22800835 0.93 PAOX (0.50) PAOXALDH1A1TSHREPHX2APP
SCHEMBL15927268 0.93 PAOX (0.45) PAOXALDH1A1TSHREPHX2APP
SCHEMBL917681 0.91 ALDH1A1 (0.59) PAOXALDH1A1TSHREPHX2CA1
SCHEMBL354553 0.91 TSHR (0.52) PAOXALDH1A1TSHREPHX2APP
SCHEMBL917570 0.89 ALDH1A1 (0.56) ALDH1A1TSHREPHX2CA1CA2
SCHEMBL918549 0.89 ALDH1A1 (0.56) ALDH1A1TSHREPHX2CA1CA2
SCHEMBL918208 0.89 ALDH1A1 (0.56) ALDH1A1TSHREPHX2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2658810-A2 METHOD FOR IMPROVING TOTAL ENERGY DEMAND IN A POST-COMBUSTION CARBON CAPTURE PROCESS WITH IONIC ABSORBENT Chevron U.S.A. Inc. (US) 2013-11-06 EP claimed
WO-2012092204-A2 METHOD FOR IMPROVING TOTAL ENERGY DEMAND IN A POST-COMBUSTION CARBON CAPTURE PROCESS WITH IONIC ABSORBENT CHEVRON U.S.A. INC. (US) 2012-07-05 WO claimed
EP-3760657-B1 HYDROPHILIZING AGENT FOR PRODUCTION OF SELF-EMULSIFYING POLYISOCYANATE COMPOSITION, SELF-EMULSIFYING POLYISOCYANATE COMPOSITION, COATING MATERIAL COMPOSITION, AND COATING FILM TOSOH CORP (JP) 2025-04-02 EP disclosed
CN-119080234-A Preparation method of enhanced denitrification and denitrification slow-release carbon source 神美科技有限公司 2024-12-06 CN disclosed
US-12134677-B2 Hydrophilizing agent for production of self-emulsifying polyisocyanate composition, self-emulsifying polyisocyanate composition, coating material composition, and coating film TOSOH CORPORATION (JP) 2024-11-05 US disclosed
US-12024533-B2 Antimicrobial organosilanes TOPIKOS SCIENTIFIC, INC. (US) 2024-07-02 US disclosed
EP-4107198-B1 POLYISOCYANATE PREPARATIONS COVESTRO DEUTSCHLAND AG (DE) 2024-03-13 EP disclosed
CN-117295486-A Cosmetic for skin penetration of hyaluronate 株式会社资生堂 2023-12-26 CN disclosed
EP-3560975-B2 IONICALLY HYDROPHILIZED POLYISOCYANATES AND ANTIOXIDANTS COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-12-06 EP disclosed
EP-3724251-B2 IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-11-22 EP disclosed
US-20230295195-A1 ANTIMICROBIAL ORGANOSILANES Tipikos Pharmaceuticals, Inc. (US) 2023-09-21 US disclosed
US-8044100-B2 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH INC. (CA) 2011-10-25 US disclosed
WO-2011051422-A2 TREATING WATER INSOLUBLE NANOPARTICLES WITH HYDROPHILIC ALPHA-HYDROXYPHOSPHONIC ACID CONJUGATES, THE SO MODIFIED NANOPARTICLES AND THEIR USE AS CONTRAST AGENTS GENERAL ELECTRIC COMPANY (US) 2011-05-05 WO disclosed
US-20110104072-A1 TREATING WATER INSOLUBLE NANOPARTICLES WITH HYDROPHILIC ALPHA-HYDROXYPHOSPHONIC ACID CONJUGATES, THE SO MODIFIED NANOPARTICLES AND THEIR USE AS CONTRAST AGENTS GENERAL ELECTRIC COMPANY (US) 2011-05-05 US disclosed
EP-1836161-A2 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES Neurochem (International) Limited (CH) 2007-09-26 EP disclosed
US-20060223855-A1 reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2006-10-05 US disclosed
WO-2006085149-A2 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2006-08-17 WO disclosed
EP-0494686-B1 Process for effecting high efficiency separations by capillary electrophoresis MILLIPORE CORP (US) 1995-03-08 EP disclosed
US-5192405-A Process for effecting high efficiency separations by capillary electrophoresis MILLIPORE CORPORATION (US) 1993-03-09 US disclosed
EP-0494686-A1 Process for effecting high efficiency separations by capillary electrophoresis MILLIPORE CORPORATION (US) 1992-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223855-A1 reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity APP, IAPP, BACE1 PAOX 2260/4885ALDH1A1 2230/4885TSHR 4277/4885
US-20110104072-A1 TREATING WATER INSOLUBLE NANOPARTICLES WITH HYDROPHILIC ALPHA-HYDROXYPHOSPHONIC ACID CONJUGATES, THE SO MODIFIED NANOPARTICLES AND THEIR USE AS CONTRAST AGENTS HAMP, SLC46A1, CD44 PAOX 821/4885ALDH1A1 1677/4885TSHR 358/4885
US-12024533-B2 Antimicrobial organosilanes ARG1, ACMSD, AAAS PAOX 2315/4885ALDH1A1 2951/4885TSHR 4128/4885
US-20230295195-A1 ANTIMICROBIAL ORGANOSILANES ARG1, ACMSD, AAAS PAOX 2315/4885ALDH1A1 2951/4885TSHR 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.